What this trial means for you
This study is active, not recruiting. It is not currently taking new participants, but its results may matter for treatments you're considering. It's studying LY3841136, Tirzepatide, Placebo for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: W8M-MC-LAA2 * Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) * Have Type 2 Diabetes * Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening W8M-MC-CWMM: * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) Exclusion Criteria: W8M-MC-LAA2 * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Have an on-going or history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (mean \>100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliters per minute (mL/min)/1.73 m2 * Have a history of acute or chronic pancreatitis * Have fasting triglycerides \>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening * All concomitant medications should be at a stable dose for at least 3 months prior to screening W8M-MC-CWMM * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have a lifetime history of suicide attempts.
Study sites by state
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- HOPE Research Institute, Phoenix
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
California
- NorCal Medical Research, Inc, Greenbrae
- Velocity Clinical Research, Huntington Park, Huntington Park
- Peninsula Research Associates, Rolling Hills Estates
- Diablo Clinical Research, Inc., Walnut Creek
Connecticut
- Stamford Therapeutics Consortium, Stamford
Florida
- Northeast Research Institute (NERI), Fleming Island
- Indago Research & Health Center, Inc, Hialeah
- New Horizon Research Center, Miami
- Suncoast Clinical Research, Inc., New Port Richey
- Charter Research - Winter Park, Orlando
- Charter Research - Lady Lake, The Villages
Idaho
- Medical Research Partners, Ammon
Illinois
- Great Lakes Clinical Trials - Andersonville, Chicago
- Great Lakes Clinical Trials - Ravenswood, Chicago
- NorthShore University Health System, Skokie
Iowa
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
Kansas
- Cotton O'Neil Diabetes & Endocrinology, Topeka
Massachusetts
- Knownwell, Needham
- Lucida Clinical Trials, New Bedford
Michigan
- Headlands Research - Detroit, Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Missouri
- StudyMetrix Research, City of Saint Peters
- Clinvest Headlands Llc, Springfield
Nevada
- Las Vegas Medical Research, Las Vegas
New York
- Dent Neurologic Institute, Amherst
- Velocity Clinical Research, Syracuse, East Syracuse
- North Suffolk Neurology, Port Jefferson Station
- Rochester Clinical Research, LLC, Rochester
North Carolina
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- Lucas Research, Inc., New Bern
Ohio
- CTI Clinical Research Center, Cincinnati
South Carolina
- Tribe Clinical Research, LLC, Greenville
Tennessee
- Quality Medical Research, Nashville
Texas
- IMA Clinical Research Austin, Austin
- Velocity Clinical Research, Dallas, Dallas
- FutureSearch Trials of Dallas, Dallas
- PlanIt Research, PLLC, Houston
- Tekton Research - Fredericksburg Road, San Antonio
- Endeavor Clinical Trials, San Antonio
- Texas Valley Clinical Research, Weslaco
Virginia
- Spectrum Medical, Inc., Danville
Washington
- Central Washington Health Services Association d/b/a Confluence Health, Wenatchee
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.